Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math

Executive Summary

Amgen walks through its price-setting model for PCSK9 inihibitor Repatha and says new outcomes data just presented at ACC provides more evidence that "prices that exist in the market are indeed value-based."

Advertisement

Related Content

Repatha Pricing Pressure Might Actually Increase After Outcomes Trial
Keeping Track: First Gliomas Imaging Agent Wins Approval; Amgen Hopes New Repatha Data Boosts Prospects
Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund
Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
Will Physician Demand For Repatha Put Pressure On Payer Restrictions?
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel